Akebia Therapeutics (AKBA) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
May 9, 2022 4:05 PM EDTNet Auryxia® (ferric citrate) product revenue of $41.4M, a 36% increase over Q1 20212022 Net Auryxia product revenue guidance of $165 - $170MOutlines refined strategic focus to deliver shareholder valueAkebia to host conference call on Monday, May 9 at 4:30 p.m. ET
CAMBRIDGE, Mass., May 9, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by... More



